Hypertension in end-stage renal disease patients.
The prevalence of hypertension is extremely high in end-stage renal disease, and is a probable contributor to the epidemic of cardiovascular disease in end-stage renal disease. However, the paucity of prospective, randomized clinical trials makes it difficult to precisely define treatment strategies. Therefore, at present time the guidelines developed by the National Kidney Foundation's Cardiovascular Disease Task Force should be followed.
Zager
P
P
Department of Internal Medicine (Nephrology), Univeristy of New Mexico, Albuquerque 87131-5271, USA. pzag@unm.edu
Nikolic
J
J
Raj
D S
DS
Tzamaloukas
A
A
Campbell
M
M
D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D051437:Renal Insufficiency / Q000150:complications*